Bcrm: Bayesian continual reassessment method designs for phase I dose-finding trials

Journal of Statistical Software

Volumn 54, Issue 13, 2013, Pages 1-26

  Sweeting, Michael ^a   Mander, Adrian ^a   Sabin, Tony ^b  

^a MRC BIOSTATISTICS UNIT   (United Kingdom)

^b AMGEN INC   (United States)

Author keywords

Bayesian adaptive designs; Continual reassessment method; Dose escalation; Dose finding; Phase I; R

Indexed keywords

EID: 84884275535     PISSN: 15487660     EISSN: None     Source Type: Journal    
DOI: 10.18637/jss.v054.i13     Document Type: Article

References (29)

1. Babb J, Rogatko A, Zacks S (1998). "Cancer Phase I Clinical Trials: Efficient Dose Escalation with Overdose Control." Statistics in Medicine, 17(10), 1103-1120.
2. Cheung K (2011). dfcrm: Dose-Finding by the Continual Reassessment Method. R Package Version 0.2-1, URL http://CRAN.R-project.org/package=dfcrm.
3. Cheung YK (2005). "Coherence Principles in Dose-Finding Studies." Biometrika, 92(4), 863-873.
4. Cheung YK, Chappell R (2000). "Sequential Designs for Phase I Clinical Trials with Late-Onset Toxicities." Biometrics, 56(4), 1177-1182.
5. Cheung YK, Chappell R (2002). "A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method." Biometrics, 58(3), 671-674.
6. Heyd JM, Carlin BP (1999). "Adaptive Design Improvements in the Continual Reassessment Method for Phase I Studies." Statistics in Medicine, 18(11), 1307-1321.
7. Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR (2008). "A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3+3 Dose Escalation Scheme in Phase I Dose-Finding Studies." Clinical Trials, 5(5), 465-477.
8. Iasonos A, Zohar S, O'Quigley J (2011). "Incorporating Lower Grade Toxicity Information into Dose Finding Designs." Clinical Trials, 8, 370-379.
9. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM (1994). "A Comparison of Two Phase I Trial Designs." Statistics in Medicine, 13, 1799-1806.
10. Lunn D, Spiegelhalter DJ, Thomas A, Best NG (2009). "The BUGS Project: Evolution, Critique and Future Directions." Statistics in Medicine, 28(25), 3049-3067.
11. Neuenschwander B, Branson M, Gsponer T (2008). "Critical Aspects of the Bayesian Approach to Phase I Cancer Trials." Statistics in Medicine, 27(13), 2420-2439.
12. Norris C, Cook J (2006). CRMSimulator Version 1.1. URL https://biostatistics.mdanderson.org/SoftwareDownload/SingleSoftware.aspx?Software_Id=13.
13. O'Quigley J (2002). "Continual Reassessment Designs with Early Termination." Biostatistics, 3(1), 87-99.
14. O'Quigley J, Chevret S (1991). "Methods for Dose Finding Studies in Cancer Clinical Trials: A Review and Results of a Monte Carlo Study." Statistics in Medicine, 10(11), 1647-1664.
15. O'Quigley J, Pepe M, Fisher L (1990). "Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer." Biometrics, 46(1), 33-48.
16. O'Quigley J, Reiner E (1998). "A Stopping Rule for the Continual Reassessment Method." Biometrika, 85(3), 741-748.
17. O'Quigley J, Shen LZ (1996). "Continual Reassessment Method: A Likelihood Approach." Biometrics, 52, 673-684.
18. O'Quigley J, Zohar S (2006). "Experimental Designs for Phase I and Phase I/II Dose-Finding Studies." British Journal of Cancer, 94(5), 609-613.
19. Paoletti X, Kramar A (2009). "A Comparison of Model Choices for the Continual Reassessment Method in Phase I Cancer Trials." Statistics in Medicine, 28(24), 3012-3028.
20. R Core Team (2013). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.
21. Shen L, O'Quigley J (1996). "Consistency of Continual Reassessment Method under Model Misspecification." Biometrika, 83(2), 395-405.
22. Spiegelhalter DJ, Thomas A, Best NG, Lunn D (2003).WinBUGS Version 1.4 User Manual. MRC Biostatistics Unit, Cambridge. URL http://www.mrc-bsu.cam.ac.uk/bugs/.
23. Storer BE (1989). "Design and Analysis of Phase I Clinical Trials." Biometrics, 45(3), 925-937.
24. Sturtz S, Ligges U, Gelman A (2005). "R2WinBUGS: A Package for Running WinBUGS from R." Journal of Statistical Software, 12(3), 1-16. URL http://www.jstatsoft.org/v12/i03/.
25. Thomas A, O'Hara B, Ligges U, Sturtz S (2006). "Making BUGS Open." R News, 6(1), 12-17. URL http://CRAN.R-project.org/doc/Rnews/.
26. Tourneau CL, Lee JJ, Siu LL (2009). "Dose Escalation Methods in Phase I Cancer Clinical Trials." Journal of the National Cancer Institute, 101(10), 708-720.
27. US Department of Health and Human Services (2010). Guidance for Industry. S9 Nonclinical Evaluation for Anticancer Pharmaceuticals. Food and Drug Administration.
28. Venier J (1999). CRM Version 1.0. URL https://biostatistics.mdanderson.org/SoftwareDownload/SingleSoftware.aspx?Software_Id=1.
29. Whitehead J (1997). "Bayesian Decision Procedures with Application to Dose-Finding Studies." International Journal of Pharmaceutical Medicine, 11, 201-208.